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Abstract  Infectious  diseases  are  one  of  the  principle  causes  of  morbidity,  mortality  and  drain
on health  resources  worldwide.  In  recent  years  there  has  been  an  increase  in  the  impact  of
respiratory infections,  particularly  in  the  Portuguese  population.  It  is  for  this  reason  that  the
Portuguese  Respiratory  Society  has  presented  a  series  of  recommendations  for  the  prevention
of respiratory  infections  in  adults.  These  recommendations  include  both  general  measures  and
vaccinations  for  ﬂu  and  pneumococcal  pneumonia.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Documento  de  Consenso  para  a  prevenc¸ão  das  infec¸ões respiratórias  no  adulto
Resumo  As  infec¸ões  respiratórias  são  uma  das  principais  causas  de  morbilidade,  mortalidade
e consumo  de  recursos  de  saúde  a  nível  global.  Nos  últimos  anos  tem-se  assistido  a  um  cres-
cente impacto  das  infec¸ões  respiratórias,  nomeadamente  na  populac¸ão  portuguesa.  Assim,Pneumonia;
Vacina  da  gripe;
Vacina  pneumocócica
a Sociedade  Portuguesa  de  Pneumologia  apresenta  um  conjunto  de  recomendac¸ões  para  a
prevenc¸ão das  infec¸ões  respiratórias  no  adulto.  Estas  recomendac¸ões  englobam  medidas  gerais
e de  vacinac¸ão  antigripal  e  antipneumocócica.
©  2013  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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tRespiratory  infections  are  among  the  principal  causes  of
morbidity,  mortality  and  of  demands  on  health  resources  at
a  global  level.1 Apart  from  the  direct  and  indirect  costs,
what  is  of  major  concern  is  the  associated  high  consumption
of  antimicrobial  drugs  and  the  consequent  increased  growth
in  resistance  to  this  class  of  medicines,  which  could  affect
the  use  of  some  types  of  antibiotics  in  the  near  future.
In  continental  Portugal,  recently  published  data  relating
to  the  period  of  2000--2009  document  the  signiﬁcant  impact
of  respiratory  infections  and,  in  particular,  of  pneumonias.
In  this  period  hospital  admissions  for  Community  Acquired
c
a
0873-2159/$  –  see  front  matter  ©  2013  Sociedade  Portuguesa  de  Pneumolo
http://dx.doi.org/10.1016/j.rppneu.2014.02.001neumonia  (CAP)  represent  3.7%  of  the  total  number  of  adult
ospital  admission  for  all  causes  in  National  Health  Service
nstitutions.2 In  the  age  groups  ≥50  and  ≥65,  hospitaliza-
ion  for  CAP  represents  5.5%  and  7.0%  of  total  admissions
espectively.2
Given  this  national  situation,  there  is  a  general  consensus
bout  the  necessity  for  a  rapid  implementation  of  measures
o  prevent  respiratory  infections  in  adults.These  preventive  measures  against  respiratory  infection
over  general  measures  and  speciﬁc  measures:  vaccination
gainst  ﬂu  and  antipneumococcal.
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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Table  1  Recommendations  for  adult  antipneumococcal  vaccination.
Age  Groups  at  risk  of  invasive
pneumococcal  disease
VPC13  VPP23
Vaccination  Vaccination  Revaccination  (after  5  years)
≥18 Immunocompromised:
Congenital  or  acquired
immunodeﬁciency
HIV/AIDS
Chronic  renal  failure
Nephrotic  syndrome
Neoplastic  diseases  (e.g.,
haematological  malignancies,
lymphomas,  multiple  myeloma)
Iatrogenic  immunosuppression
(e,g.,  long-term  systemic
corticotherapy,  chemotherapy
and  radiotherapy)
Solid  organ  transplant
Recommended Recommended  Recommended
Anatomical  or  functional
asplenia
(e.g.,  sickle  cell  anaemia  and
other  hemoglobinopathies,
congenital  or  acquired
asplenia)
Recommended Recommended Recommended
Cerebrospinal  ﬂuid  leaks  Recommended  Recommended  Recommended
Cochlear  implants  Recommended  Recommended  Recommended
≥50 Chronic  co-morbidities:
Chronic  respiratory  diseases
(includes  chronic  asthma  under
inhaled  corticosteroid)
Chronic  cardiac  diseases
(excludes  hypertension  alone)
Chronic  liver  diseases  (e.g.,
cirrhosis)
Diabetes  mellitus  (excludes
patients  controlled  by  diet
only)
Recommended  Recommended  Recommended
≥65 Individuals  aged  ≥65  Recommended  Recommended  Not  recommended
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n  the  general  measures,  related  to  host  defences,  the  fol-
owing  are  recommended3:
 smoking  cessation;
 control  of  chronic  illnesses  (diabetes  mellitus,  COPD,  con-
gestive  heart  failure,  chronic  renal  failure,  chronic  liver
disease,  HIV/AIDS  infection,  etc.);
 judicious  use  of  immunosuppressive  therapies  (including
corticosteroids); alcohol  counselling  (including  acute  intoxication  and
chronic  alcoholism);
 advice  about  dealing  with  cases  of  drug  addiction;
 adequate  nutritional  status;
t
v
o
t gamma  globulin  IV  immunotherapy  in  selected  patients
(IgG  deﬁciency,  multiple  myeloma,  chronic  lymphocytic
leukaemia,  transplant  patients).
nti-ﬂu vaccination
his  endorses  the  Directorate-General  of  Health  recom-
endation  for  vaccination  against  seasonal  ﬂu  for  the
urrent  season.4 Health  professionals  and  other  profession-
ls  involved  in  front-line  health  care  are  a  priority  group
or  vaccination,  because  of  the  increased  risk  of  contract-
ng  the  illness  and  transmitting  it  to  their  families  and
heir  patients.  Setting  an  example  and  the  counselling  about
accination  given  by  health  professionals  represent  one
f  the  principle  success  factors  in  keeping  to  vaccination
argets.
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Table  2  Recommendations  for  antipneumococcal  vaccination  in  speciﬁc  circumstances  (adapted  from1,13).
Condition  Vaccination  recommendations  (individuals  not  vaccinated)
HIV/AIDS  Early,  preferably  with  lymphocytes  TCD4+≥  200/mm3;  if
TCD4+ <  200/mm3,  vaccinate  without  waiting  for  immune
reconstruction  and  consider  revaccination  after
TCD4+≥  200/mm3
Surgical  splenectomy In  elective  surgery,  at  least  2  weeks  before  surgery;  in
unplanned  surgery,  vaccinate  2  weeks  after  surgery
Autoimmune  diseases  Early  and  before  starting  immunosuppressive  therapy
Waiting for  a  solid  organ  transplant  Early,  at  least  2--4  weeks  before  transplant
Solid organ  transplant  Start  vaccination  6  months  after  transplant
Transplant  of  hematopoietic  cells  Start  vaccination  3--6  months  after  transplant
Neoplastic  diseases  in  chemotherapy  and/or  radiotherapy 10--14  days  before  treatment  or  3  months  after  ﬁnishing
chemotherapy  or  radiotherapy.  If  the  vaccine  is  administered
during  the  course  of  chemotherapy  consider  whether  to
revaccinate  3  months  after  ﬁnishing  treatment
VPC13
VPC13
≥ 8 weeks
≥ 8 weeks
≥ 5 years
≥ 5 years
≥ 1 year
VPP23
VPP23
VPP23
VPP23
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In  Portugal  two  pneumococcal  vaccines  are  available  for
adults  aged  18  and  above,  a  pneumococcal  polysaccharide
vaccine  23-valente  [(Pneumo  23®)  VPP23]  with  23  serotypes
(1,  2,  3,  4,  5,  6B,  7F,  8,  9N,  9V,  10A,  11A,  12F,  14,  15B,  17F,
18C,  19A,  19F,  20,  22F,  23F,  33F)  and  a  pneumococcal  con-
jugate  vaccine  13-valente  [(Prevenar  13®)  VPC13]  with13
serotypes  (1,  3,  4,  5,  6A,  6B,  7F,  9V,  14,  18C,  19A,  19F,
23F).  Both  vaccines  are  intramuscular  and  VPP23  can  also
be  administered  subcutaneously.5,6
For  adults,  vaccines  are  indicated  for  the  prevention  of
invasive  pneumococcal  diseases  by  the  serotypes  included
in  the  vaccine.  The  bacteraemia  secondary  to  pneumonia  is
the  main  manifestation  of  invasive  pneumococcal  disease  in
adults,  representing  about  75%  of  cases  of  invasive  disease
in  the  adult  population7 and  more  than  80%  in  those  ≥65.8
At  the  present  time,  we  are  waiting  for  the  results
of  studies  about  the  efﬁcacy  of  VPC13  in  the  prevention  of
pneumonia  in  adults.
Epidemiological  surveillance  programmes  on  invasive
pneumococcal  disease  and  its  serotypes  at  a  national
level  are  crucial  for  the  evaluation  of  the  effectiveness
of  anti-pneumococcal  vaccines  and  recommendations  for
their  utilization.  According  to  the  latest  data  available  at
a  national  level,  relating  to  the  period  2006--2008,  from
a  total  of  1100  isolates  of  Streptococcus  pneumoniae  in
adults  with  an  invasive  pneumococcal  disease,  68%  of  the
serotypes  identiﬁed  were  included  in  VPC13  and  84%  in
VPP23.9
Table  1  presents  recommendations  for  antipneumococcal
vaccinations  according  to  the  risk  of  invasive  pneumococcal
disease.7,8,10--13
In  adults  who  are  indicated  for  antipneumococcal  vacci-
nation,  the  following  dosing  schedule  is  suggested10:
T
f
aigure  1  Schedule  for  antipneumococcal  vaccination  in  non-
accinated  individuals  or  previously  vaccinated  with  VPP23.
 adults  who  have  not  previously  been  vaccinated  should
ﬁrst  receive  VPC13  followed  by  a  dose  of  VPP23  at  least  8
weeks  later;
 adults  who  have  already  been  vaccinated  with  VPP23
should  only  receive  VPC13  at  least  one  year  after  the  last
vaccination  of  VPP23;
 for  adults  with  indication  for  revaccination  with  VPP23,
the  second  dose  must  only  be  given  at  least  5  years  after
the  ﬁrst  dose  of  VPP23  and  at  least  8  weeks  after  admin-
istration  of  VPC13.
Revaccination  with  VPC13  is  not  recommended  and  in
he  case  of  VPP23,  revaccination  should  only  be  done  once
Fig.  1).
Pneumococcal  vaccines  should  be  administered  at  the
ost  propitious  time  for  the  immune  system  to  respond;
able  2 presents  an  optimization  calendar  of  vaccinations
or  certain  clinical  conditions  (adapted13).
The  inﬂuenza  and  pneumococcal  vaccines  can  be  given
t  the  same  time,  preferably  in  different  arms.
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onclusions
he  recommendations  presented  in  this  document  should  be
ubject  to  clinical  judgement  in  relation  to  the  individual
ases.
This  document  will  be  subject  to  periodic  revisions  in
rder  to  include  the  scientiﬁc  evidence  of  future  studies
nd  knowledge  about  other  measures  and  vaccines  like,  for
xample,  the  whooping  cough  which  is  available  and  recom-
ended  in  some  European  countries.14,15
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